Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Nyrada Trial Advances As Dosed Patients Rise And Site Network Expands

Nyrada Inc. (NYR) · Health care

NYR: $0.460 -6.12% · MC: $133M

Nyrada says five patients have now been dosed in its PROTECT-MI Phase IIa trial, up from three at its previous update, with five sites active and three more expected to open by the end of November. The company is targeting final patient dosing in mid-2027 and preliminary results in the second half of 2027, while its US drug application submission remains targeted for the first half of 2027. Separately, Nyrada has issued the CDIs and attaching options associated with its recent capital raising.

Source announcements: 2026-10-30 08:19 to 2026-10-30 10:07 Sydney time
Story updated 2026-10-30 10:10 Sydney time
SourcesPROTECT-MI Phase IIa Clinical Trial Update No 4Application for quotation of securities - NYRApplication for quotation of securities - NYR
Comments